Compare Medpace Holdings Inc (MEDP) vs Msci Inc (MSCI) Price & Performance

MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.

Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.

MSCI trades at $559.73, down 0.59% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported Q2 2026 earnings of $4.94 per share, slightly missing expectations, but maintains strong fundamentals with a 40.73% net income margin and $3.13 billion in 2025 revenue. Recent developments include the completed acquisition of First Street and a strategic partnership with UBS to enhance private markets transparency.

The stock presents a compelling opportunity with a consensus price target of $728.14, implying significant upside, supported by robust profitability and recurring revenue streams. Key risks include high valuation multiples, such as a P/E of 30.71, and substantial long-term debt of $4.51 billion, which could pressure equity if interest rates rise.